Progress toward a Lyme disease vaccine is giving public health observers reason for optimism, according to a health bulletin published by MassLive out of Westfield, Massachusetts.
The bulletin described the news surrounding a Lyme vaccine as encouraging, a notable development for a region of the country where tick-borne illness is a persistent seasonal concern. The northeastern United States, including Massachusetts, has some of the highest rates of Lyme disease in the country, making vaccine development a matter of particular local interest.
Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected black-legged ticks, commonly known as deer ticks. Symptoms can include fever, fatigue, headache, and a characteristic skin rash. If left untreated, the infection can spread to joints, the heart, and the nervous system.
There is currently no approved Lyme disease vaccine available to the public in the United States. A vaccine called LYMErix was approved by the Food and Drug Administration in 1998 but was withdrawn from the market in 2002 by its manufacturer, SmithKline Beecham, amid declining sales and controversy over reported side effects, though regulators had not found the vaccine to be unsafe.
Since then, researchers and pharmaceutical companies have continued working toward a new vaccine. Pfizer and its partner Valneva have been among the most advanced in clinical development, with their candidate vaccine VLA15, known commercially as Ospelura, completing late-stage trials. That candidate has shown promise in protecting against multiple strains of Borrelia.
The Westfield health bulletin did not detail which specific development it described as encouraging, but the broader context of Lyme vaccine research suggests the field is closer to a viable product than it has been at any point since LYMErix was pulled. For communities in tick-dense areas of New England and the mid-Atlantic states, a new vaccine could significantly reduce the burden of a disease that affects an estimated 476,000 Americans each year, according to the Centers for Disease Control and Prevention.
Public health officials have long urged residents in high-risk areas to take preventive measures including wearing long sleeves, using insect repellent, and performing tick checks after time outdoors. A vaccine would add a tool to those existing precautions.
The timing of any potential FDA review and approval process for a Lyme vaccine candidate has not been specified in the available reporting.
